INBX Inhibrx 8-K2021Inhibrx Announces Phase 1 Dose Escalation Results of
5 Jan 21
Content Analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
|
|
INBX 8-K Filings
- 13 Jan 21 Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients
- 5 Jan 21 Inhibrx Announces Phase 1 Dose Escalation Results of
- 13 Nov 20 Inhibrx Reports Financial Results for the Third Quarter 2020 and Announces Amended Loan Agreement with Oxford
- 12 Nov 20 Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients
- 11 Sep 20 Regulation FD Disclosure
Filing View
Search this filing
Table of Contents
Get all this for free
- Email alerts for new filings that match keywords or companies
- Plot, compare & download financial data
- 10-K & 10-Q redlined comparisons
- Advanced filing search & analysis
- Sentiment analysis for financial filings
- Favorites, search history, and more…